Rigel Pharmaceuticals (RIGL) Income towards Parent Company (2010 - 2026)

Rigel Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 24.39% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $364.2 million (up 879.7% YoY), while the FY2025 annual figure was $367.0 million, up 1999.08% from the prior year.
• Income towards Parent Company was $8.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $268.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $268.1 million in Q4 2025 to a low of -$27.4 million in Q1 2022.
• Historically, Income towards Parent Company has averaged $18.2 million across 5 years, with a median of $737000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company slumped 169.48% in 2022, then soared 5887.67% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at $1.4 million in 2022, then slumped by 47.39% to $737000.0 in 2023, then soared by 1845.86% to $14.3 million in 2024, then surged by 1769.22% to $268.1 million in 2025, then slumped by 96.77% to $8.7 million in 2026.
• The last three Income towards Parent Company figures came in at $8.7 million (Q1 2026), $268.1 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.